综合性长非编码RNA分析和宫癌的复发预测使用复发神经网络
Geeitha Senthilkumar1, Renuka Pitchaimuthu1, Prabu Sankar Panneerselvam2
1Department of Information Technology, M. Kumarasamy College of Engineering, Thalavapalayam, Karur 639113, Tamil Nadu, India.
Diagnostics (Basel, Switzerland)
|November 27, 2025
概括
一个新的9个长的非编码RNA (lncRNA) 签名,结合深度学习,有效地根据患者患子宫癌复发风险进行分层,提高了预后准确性.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 再发性子宫癌对患者的生存构成重大威胁.
- 准确的预后模型对于识别高风险个体至关重要.
- 目前的模型需要通过集成的临床和分子数据来增强.
研究的目的:
- 将临床数据与GSE44001数据集集集成,以确定宫癌复发风险因素.
- 将患者分为高风险,中风险和低风险组.
- 为了识别长非编码RNA (lncRNA) 基因签名的复发性宫癌.
主要方法:
- 利用来自NCBI GEO数据库的GSE44001数据集,专注于138名复发性宫癌患者.
- 使用GENCODE注释工具过和分析长非编码RNA (lncRNAs).
- 采用最小绝对收缩选择运算器 (LASSO) 来根据lncRNA表达和系数进行特征选择和风险值分配.
主要成果:
- 一个复发神经网络 (RNN) 长期短期记忆模型显示出预后价值,高风险患者的无复发生存时间较短 (p < 0.05).
- 特定的lncRNA标记物 (ATXN8OS,C5orf60,INE1) 与疾病复发有关.
- 其他标记物 (KCNQ1DN,LOH12CR2,RFPL1S,KCNQ1OT1,EMX2OS) 与早期或中等阶段的诊断相关.
结论:
- 一个九个lncRNA签名显示出预测宫癌复发的巨大潜力.
- 这种 lncRNA 签名与深度学习的整合提供了一个强大的风险分层方法.
- 这种方法可以帮助识别可能受益于加强监测或治疗的患者.
相关概念视频
lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
lncRNA - Long Non-coding RNAs
3.5K
3.5K
Non-LTR Retrotransposons
13.1K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.1K
